Ceftriaxone Injection 1g (Ceftriaxone Sodium Hydrate)
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Ilhwa Co., Ltd.
MFDS item code 201604531 · Notified 2016.07.22 · Insurance code 640903261
Treatment of infections in the respiratory system (pneumonia, bronchitis) and genitourinary system (gonorrhea)
This medication is effective against a variety of bacterial infections and is used for respiratory infections such as pneumonia and bronchitis as well as otolaryngological infections. It also helps treat genitourinary infections like renal and urinary tract infections, gonorrhea, and plays a significant role in preventing infections during and after surgery. It is effective for bone and joint infections, skin and wound infections, soft tissue infections, as well as gastrointestinal infections like peritonitis, cholecystitis, cholangitis, and in patients with weakened immune systems. It is also used to treat meningitis, improving various infection symptoms.
Adults and children aged 12 and older: administer 1-2 g (potency) of ceftriaxone as an intravenous or intramuscular injection once daily. For severe or moderately sensitive pathogen infections, the dose can be increased to 4 g (potency) once daily. For the treatment of gonorrhea, a single intramuscular injection of 250 mg (potency) is recommended. For preventing postoperative infections, administer 1-2 g (potency) depending on the risk of infection, 30-90 minutes before surgery.
Neonates (up to 14 days old): administer 20-50 mg (potency) per kg of body weight once daily, not exceeding 50 mg (potency) per kg. Infants and children (15 days to 12 years):
This medication must not be mixed or administered concurrently with solutions containing calcium or other medications. Particularly in neonates, there is a risk of precipitation when calcium and this medication are combined, so it should not be administered. Patients allergic to this medication or with hypersensitivity to cephalosporin or penicillin antibiotics should not use it, and it should not be administered to premature infants and neonates with bilirubin binding impairment. Those with a history of drug allergies, individuals with severely impaired kidney function, elderly patients, and patients in poor general condition should use this medication with caution. This medication can cause various side effects primarily in blood, digestive system, skin, liver, and kidneys, so symptoms should be closely monitored during administration. If severe allergic reactions or shock symptoms occur, treatment should be immediately discontinued, and appropriate emergency measures should be taken. This medication should be used only for the necessary duration to prevent resistance; it is advisable to check for allergies before administration. During treatment, regular assessments of liver and kidney function and blood tests should be conducted. There is no specific antidote for overdose, so symptomatic treatment should be provided. Caution is advised when driving or operating machinery, as side effects like dizziness may occur. Women who are pregnant or breastfeeding should consult a doctor before using this medication, as it may affect the fetus or neonate. It is safer not to administer this medication to children, particularly neonates and premature infants, as it may increase the risk of bilirubin encephalopathy. Elderly patients may experience side effects more easily due to decreased bodily functions, so administration should be done carefully regarding dosage and intervals. This medication can interact with other drugs, so caution is needed, especially when used with diuretics or aminoglycoside antibiotics that may affect the kidneys. When administering, do not inject simultaneously with calcium-containing solutions; ensure to separate the injection ports or thoroughly wash them before administration in sequence. Prepared solutions should be used as soon as possible, and it is advisable not to store them for excessive periods.
Urticaria, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe rash with high fever, blisters, skin peeling, oral/ocular mucosal pain, shortness of breath or difficulty breathing, asthma attacks, abnormal breathing accompanied by cough and fever, jaundice (yellowing of skin or eyes), profound lethargy, sudden and severe headaches, thunderclap headaches, seizures, altered consciousness, visual disturbances, paralysis, urination issues
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air or moisture ingress and should ideally be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's efficacy.
White to pale yellow crystalline powder filled in a colorless, transparent vial
1 vial, 10 vials
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Ilhwa Co., Ltd.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
Boryung Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 0.5g
Prescription medication
(Boryung)
Ceftriaxone Sodium Hydrate 1g
Prescription medication
(Co., Ltd.) Joongheun Pharmaceutical
Ceftriaxone Sodium Hydrate 1g
Injections · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 500mg
Prescription medication
International Pharmaceutical Co., Ltd.
Ceftriaxone Sodium Hydrate 1g
Prescription medication
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.